<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>18</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Clinical Efficacy and Prognostic Factors of Chemoreduction Combined with Topical Treatment for Advanced Intraocular Retinoblastoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>7805</FirstPage>
			<LastPage>7809</LastPage>
			<ELocationID EIdType="pii">29298</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br/&gt;&lt;b&gt;Objective&lt;/b&gt;: To explore the clinical efficacy and prognostic factors of chemoreduction combined with topicaltreatment of advanced intraocular retinoblastoma (RB). Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: A total of 22 eyes from 17children with RB were selected for the study and treated with chemoreduction combined with topical cryotherapy,transpupillary thermotherapy (TTT) or episcleral plaque brachytherapy. Clinical and follow-up data wereretrospectively analyzed. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: All children received 2~6 courses of chemoreduction treatment, (4.5±0.8courses on average); 17 eyes from 13 children were treated by chemoreduction combined with cryotherapy orTTT and 5 eyes from 4 children with chemoreduction combined with 125I episcleral plaque brachytherapy. Theeye retention rate was 81.8% (18/22), among which 38.9% (7/18) featured restored or maintained good vision.Postoperative follow-up period was 7 to 34 months, (18.6 ± 5.2 months on average). The recurrence rate was41.2% (7/17), among which 57.1% (4/7) were controlled by supplementing or appending cryotherapy or TTTtreatment during the follow-up period. The tumor basal diameter and thickness were significantly reduced(P&lt;0.05 or P&lt;0.01) after treatment. All children demonstrated different degrees of hair loss, 70.6% (12/17) withdifferent degrees of gastrointestinal reactions, 5.88% (1/17) with neutropenia and 11.8% (2/17) being seriouslyinfected during the chemotherapeutic treatment. Univariate and logistic regression analysis showed that tumorbasal diameter before treatment had a significant effect on the prognosis (P&lt;0.01). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Chemoreductioncombined with topical therapy can effectively control RB in the short term, and tumor basal diameter beforetreatment is an independent risk factor for prognosis.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">retinoblastoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">chemoreduction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cryotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">transpupillary thermotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Brachytherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">plaque</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_29298_235b04be6807fc619b1096862b6bd4be.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
